Changing stroke rehab and research worldwide now.Time is Brain! trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 523 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

My blog is not to help survivors recover, it is to have the 10 million yearly stroke survivors light fires underneath their doctors, stroke hospitals and stroke researchers to get stroke solved. 100% recovery. The stroke medical world is completely failing at that goal, they don't even have it as a goal. Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It lays out what needs to be done to get stroke survivors closer to 100% recovery. It's quite disgusting that this information is not available from every stroke association and doctors group.

Thursday, May 16, 2019

Experimental antiplatelet compound for acute stroke shows promise

Well, further research needed since this was done on healthy volunteers not persons who might need the drug.  This does make the assumption you know what those anticlotting therapies this may replace. So ask your doctor about this, it has only been out a month. No knowledge then your doctor is out-of-date, why are you seeing them? It also means your stroke hospital doesn't have a system to keep their stroke medical professionals up-to-date on stroke research. So the hospital is incompetent also, along with the president and the board of directors. We have to clean out a lot of dead wood in stroke.

Experimental antiplatelet compound for acute stroke shows promise

ScienceDaily | April 19, 2019
An experimental antiplatelet compound inhibited clot formation without increasing bleeding, a common and potentially dangerous side effect of current anticlotting therapies, according to new phase 1 research in Arteriosclerosis, Thrombosis and Vascular Biology, an American Heart Association journal.

The results of the industry-sponsored trial are based on a first-in-human study of the new compound called ACT017. The findings suggest that the drug may provide an effective and safer alternative to current antiplatelet therapies used in stroke patients, which can also increase the risk for dangerous bleeding in the brain.
"There is a clear need for a novel antiplatelet agent that resolves platelet aggregation and clot formation without raising the risk for bleeding. Such a therapy would considerably improve and expand our current therapeutic arsenal for the treatment of acute stroke," said Martine Jandrot-Perrus, MD, PhD, study senior author and scientist at France's National Institute of Health and Medical Research (INSERM) and a consultant for Acticor-Biotech, the company that developed the compound and funded the trial.
The drug is an antibody-based compound that inhibits blood platelet aggregation (or clumping) and clot formation by precisely targeting a protein called platelet glycoprotein VI (GPVI) found in platelets. This protein is critical for clot formation—a process marked by the clumping of platelets— but it does not play a role in regulating bleeding. This feature renders the GPVI protein an ideal target for a drug that inhibits the clumping of platelets but does so without increasing the risk for bleeding.
The trial involved 36 healthy volunteers (23 women and 13 men), ages 22 to 65, divided into six groups. In each group, six participants received intravenous infusions over 6 hours with various doses of the drug (ranging from 62.5 mg to 2,000 mg).
The drug was well-tolerated at all doses, without serious side effects. Notably, the compound did not appreciably prolong bleeding time, a marker indicating increased risk for dangerous bleeds. The study also showed that the extent and duration of the therapeutic effect was dose-dependent, reaching maximum effectiveness and duration at 2,000 mg. The most common side effects were mild to moderate headache and head discomfort, which resolved during the study.
"Our results are quite encouraging because they show the candidate compound is well-tolerated at doses even twice as high as the ones targeted for a future treatment and without any signs of bleeding," Jandrot-Perrus said. "Another encouraging finding is the fact that the drug's action on platelets is rapid, specific, and largely reversible within 24 hours."
To read more, click here.

No comments:

Post a Comment